Cytostatic agents renal cancer

Erythropoietin (Eprex ) is physiologically produced in the kidney and regulates proliferation of committed progenitors of red blood cells. It is used to substitute erythropoietin in severe anemias due to end stage renal disease or treatment of cancer with cytostatic agents. Side effects include hypertension and increased risk of thrombosis. 

An unusual case of rapidly fatal renal failure reported in 1993 could reflect an interaction between tamoxifen and one or more cytostatic agents, with mitomycin C a prime suspect in a series of breast cancer patients some 10% of those treated both with tamoxifen and a cytostatic agent developed abnormal renal function, progressing towards various stages of hemolytic-uremic syndrome (118). 

---